Please assess the completion status of the following clinical trial:

Trial Title: Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women who have \>/= 80 mL blood loss during their menstrual cycles and desire contraception~Exclusion Criteria:~* Post menopausal menstrual cycle \< 21 days or \> 35 days~* Pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levonorgestrel Intrauterine System (LNG IUS) 20µg per 24 hours (Type: EXPERIMENTAL): Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
- Medroxyprogesterone acetate (MPA) (Type: ACTIVE_COMPARATOR): Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).